Biomarin Pharmaceutical BMRN
-
4 Highly Liquid Biotech Stocks With Strong Receivable Trends
By Kapitall : Interested in the high-growth prospects of the biotech industry? For a closer look at some interesting biotech names, we ran a screen. We began by screening the biotech sector for stocks with strong liquidity, with current ratios above 3. The current ratio is current assets/current ...
-
Noteworthy Insider Buys Last Week In 2 Beaten Down Biotechs, With 4 Other Buys And Sells
By Ganaxi Small Cap Movers : trades. Complete Story »
-
6 High-Growth Biotech Stocks Analysts Rate As Buys
By ZetaKap : Interested in gaining exposure to biotechnology companies? Do you prefer stocks that are projected to grow over the long term? Do you prefer investing in stocks that analysts have weighed in on? If so, here's a list you might be interested in. EPS growth (earnings per share growth) ...
-
6 High-Growth Biotechnology Stocks With Great Liquidity
By ZetaKap : Interested in biotechnology companies? Do you value companies holding large amounts of cash? Do you prefer stocks with high projected earnings over the next year? If so, you'll probably like this list. The Current ratio is a liquidity ratio used to determine a company's financial ...
-
6 Mid-Cap Biotechnology Stocks With Great Liquidity And Rated Buy Or Better
By ZetaKap : Are you looking for mid-sized companies that still have room to grow? Are you interested in gaining exposure to biotechnology companies and companies with high liquidity? Do you prefer stocks that analysts rate as 'Buy', or better? If so, here are some ideas to start your stock search.
-
Analyzing Noteworthy Insider Trades Last Week In Regeneron, Covidien, And Other Healthcare Stocks
By Ganaxi Small Cap Movers : We present here two noteworthy insider buys and eight noteworthy insider sells in the healthcare sector from Wednesday through Friday's (May 2nd, 3rd, and 4th, 2012) over 1,100 separate SEC Form 4 (insider trading) filings, as part of our daily and weekly coverage of ...
-
Raptor Pharmaceuticals: Overlooked And Primed For Rapid Growth
… process. RP103 met the primary end point and there were no serious safety concerns. CEO and CSO were co-founders of BioMarin ( BMRN ). RP103 is also being developed for Huntington's disease, a genetic neurodegenerative disease with a phase II ongoing …
-
BioMarin's R&D Costs Continued to Rise in the First Quarter, But Pipeline Looks Strong
BioMarin BMRN reported first-quarter results that largely matched our expectations, and we're maintaining our fair value estimate. Overall …
-
Threshold Pharmaceuticals: TH-302 Phase IIb Clinical Results In First-Line Pancreatic Cancer
By Andrew McDonald : By Andrew McDonald, Ph.D. and Ning Yang, Ph.D. On April 2, 2012, Dr. Mitesh J. Borad, the principal investigator of Phase IIb clinical trial for Threshold Pharmaceutical's ( THLD ) leading drug candidate TH-302 in pancreatic cancer indication, presented the detailed results of
-
BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
BioMarin Pharmaceutical ( BMRN ) Q1 2012 Earnings Call April 26, 2012 5:00 pm ET Executives Eugenia Shen - Jean-Jacques Bienaimé - Chief Executive Officer …